As the Fed begins its two-day policy meeting Tuesday, markets will get a look at how consumers behaved just before the government shut down.» Read More
Allergan filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladders. David Pyott, chairman & CEO of Allergan, offers insight on Botox and its many uses.
David Pyott, Allergan chairman/CEO, discusses the company's earnings, and products in the big pharma pipeline, with Mad Money's Jim Cramer.
Allergan is finding ways to deliver returns for investors in a struggling market and discussing business strategies behind the brand, with David Pyott, Allergan chairman/CEO.
Mad Money host Jim Cramer explains why Allergan isn't about to fall off a patent cliff like so many other big pharma companies. David Pyott, Allergan chairman, president & CEO weighs in on the company's earnings.
Making a case for lap-band surgery and discussing the benefits to patients and insurance companies, with David Pyott, Allergan CEO.
David Pyott, Allergan chairman & CEO, discusses earnings and the aesthetics business, including Botox.
Insight on why the Botox-maker is raising its full-year sales and earnings outlook, with David Pyott, Allergan chairman/CEO.